Arch Venture Management
$1.1B 13F equity value
13 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Arch Venture Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PBLS | PARABILIS MEDICINES INC | 6,412,780 | $176M | 16.0% |
| BEAM | BEAM THERAPEUTICS INC | 4,540,132 | $156M | 14.2% |
| RAPP | RAPPORT THERAPEUTICS INC | 3,728,738 | $155M | 14.1% |
| SPTX | SEAPORT THERAPEUTICS INC | 6,294,951 | $137M | 12.4% |
| ERAS | ERASCA INC | 7,091,557 | $130M | 11.8% |
| VIR | VIR BIOTECHNOLOGY INC | 12,694,163 | $129M | 11.8% |
| MAZE | MAZE THERAPEUTICS INC | 4,120,053 | $123M | 11.2% |
| LYEL | LYELL IMMUNOPHARMA INC | 3,247,162 | $46M | 4.1% |
| GENB | GENERATE BIOMEDICINES INC | 1,944,426 | $33M | 3.0% |
| TXG | 10X GENOMICS INC | 217,834 | $8M | 0.8% |
Track Arch Venture Management's 13F portfolio: $1.1B in reported holdings, 13 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}